Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 05, 2016; 86 (16 Supplement) April 21, 2016

Effect of MD1003 (High Doses of Biotin) in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis (MS-ON): Results of a Pivotal Randomized Double Masked Placebo Controlled Study (S49.005)

Ayman Tourbah, Carl Arndt, Alain Vighetto, Véronique Deburghgraeve, Jean Pelletier, Caroline Papeix, Christine Lebrun-Frenay, Pierre Labauge, Michel Clanet, Ahmed Toosy, David Laplaud, Patrick Vermersch, Thibault Moreau, Marc Debouverie, Pierre Clavelou, Olivier Heinzlef, Jerome De Seze, Gilles Defer, Frederic Sedel, Olivier Gout
First published April 4, 2016,
Ayman Tourbah
1Reims France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carl Arndt
8CHU Reims Reims France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alain Vighetto
15Hopital Neuro Pierre Wertheimer Lyon France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Véronique Deburghgraeve
9Neurology CHU Rennes Rennes France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean Pelletier
18Hospital Timone Adultes Marseille, Cedex 5 France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Papeix
12GH Pitie Salpetriere Paris France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Lebrun-Frenay
6CHU Nice Nice France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Labauge
4CHU Monpellier Montpellier, Cedex 4 France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel Clanet
7CHU Purpan Toulouse France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ahmed Toosy
20UCL Institute of Neurology London United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Laplaud
5CHU Nantes Nantes France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Vermersch
2CHR de Lille Lille France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thibault Moreau
3CHU Dijon Dijon France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Debouverie
16Hospital Central Nancy France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Clavelou
14Hopital Gabriel Montpied Clermont Ferrand France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Heinzlef
17Hospital De Poissy Poissy France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerome De Seze
10CHU Strasbourg Strasbourg France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilles Defer
13Hopital Cote De Nacre Caen France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederic Sedel
19MedDay Pharmaceuticals Paris France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Gout
11Fondation De Rothschild Paris France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Effect of MD1003 (High Doses of Biotin) in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis (MS-ON): Results of a Pivotal Randomized Double Masked Placebo Controlled Study (S49.005)
Ayman Tourbah, Carl Arndt, Alain Vighetto, Véronique Deburghgraeve, Jean Pelletier, Caroline Papeix, Christine Lebrun-Frenay, Pierre Labauge, Michel Clanet, Ahmed Toosy, David Laplaud, Patrick Vermersch, Thibault Moreau, Marc Debouverie, Pierre Clavelou, Olivier Heinzlef, Jerome De Seze, Gilles Defer, Frederic Sedel, Olivier Gout
Neurology Apr 2016, 86 (16 Supplement) S49.005;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objectives: To report the results of the MS-ON study evaluating the efficacy of MD1003 over placebo in relapsing remitting or progressive MS patients with visual loss related to optic neuropathy Background: MD1003 (High dose of Biotin) has recently demonstrated efficacy in decreasing progression and improving walking disability in patients with primary and secondary progressive multiple sclerosis (MS) Methods: This is a randomized, double-blind, multicenter, placebo-controlled (2:1) trial of oral biotin 300 mg / day in MS patients with visual loss related to optic neuropathy. All patients had at least one eye with visual acuity ETDRS score ≤ 72 for at least 6 months. We included patients either with visual loss following an optic neuritis relapse (ON relapses, n=62) or patients with chronic progressive optic neuritis (progressive ON, n=31). Treatment duration was 24 weeks. The primary endpoint was the mean change in 100[percnt] contrast visual acuity at “month 6” from baseline of the selected eye (defined as the eye with the worst visual acuity and showing worsening during the past 3 years). Other endpoints included visual evoked potentials, automated visual field perimetry, optic coherence tomography and patient reported outcome measures. Results: The last patient completed the study in August 2015. The database was locked in late September 2015. Full statistical analyses are awaited. Baseline characteristics: 93 MS patients (62 with On relapses and 31 with progressive ON) from 19 sites across France and UK were randomized. Results of primary and secondary endpoints will be presented during the meeting. Conclusions: Results will be discussed in the context of development of high doses of pharmaceutical grade biotin as a novel treatment in MS. The study was supported by MedDay Pharmaceuticals

Disclosure: Dr. Tourbah has received personal compensation for activities with Biogen Idec, MedDay Pharmaceuticals, Sanofi-Genzyme, Novartis, Merck Serono, and Teva Pharma as a consultant/lecturer. Dr. Arndt has received personal compensation for activities with Bayer as a member of the scientific advisory board. Dr. Vighetto has nothing to disclose. Dr. de Burghgraeve has nothing to disclose. Dr. Pelletier has nothing to disclose. Dr. Papeix has nothing to disclose. Dr. Lebrun Frenay has nothing to disclose. Dr. Labauge has nothing to disclose. Dr. Clanet has nothing to disclose. Dr. Toosy has received personal compensation for activities with Biogen Idec. Dr. Laplaud has nothing to disclose. Dr. Vermersch has received personal compensation for activities with Biogen Idec, Sanofi, Bayer, Novartis, Merck Serono, GlaxoSmithKline, and Almirall. Dr. Vermersch has received research support from Biogen Idec, Sanofi, Bayer, and Merck Serono. Dr. Moreau has received personal compensation for activities with Biogen Idec, Sanofi-Aventis Pharmaceuticals, Genzyme corporation, Teva Neuroscience, Bayer Schering, Merck Serono, Novartis, and Almirall as a consultant. Dr. Debouverie has received research support from Biogen Idec, Genyzyme, Merk Serono, and Novartis. Dr. Clavelou has received personal compensation for activities with Genzyme, Teva, Novartis, Almirall, and Biogen Idec. Dr. Heinzlef has received personal compensation for activities with Genzyme as an advisory board member, from Almirail as a speaker, and Merck Serono as a consultant. Dr. De Seze has nothing to disclose. Dr. Defer has received research support from Novartis and Merck Serono Dr. Sedel holds stock and/or stock options in Medday Pharmaceuticals. Dr. Gout has nothing to disclose.

Thursday, April 21 2016, 1:00 pm-3:00 pm

  • Copyright © 2016 by AAN Enterprises, Inc.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 98 (21)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise